Currently viewing: | Our performance | Next: Achieving impact through our sustainability pillars
A high-level overview of our performance over the past year and the outlook for each of our strategic objectives is set out in the pages that follow.
Commercial Pharmaceuticals
Manufacturing
Products which generally require a prescription from a healthcare professional. Primary therapeutic areas are anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids.
Revenue (%)
25%
of Group revenue
36%
of Group gross profit
Products that do not require a prescription and are mainly sold through retail pharmacies and the fast moving consumer goods sector, where brand recognition, marketing, and interactions with pharmacists play a key role in influencing consumer choices.
Revenue (%)
22%
of Group revenue
29%
of Group gross profit
Aspen’s injectable products are primarily administered in hospitals and also prescribed and administered by either physicians or in a retail pharmacy environment. These products focus on key therapeutic areas, including anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement therapies.
Revenue (%)
21%
of Group revenue
28%
of Group gross profit
Aspen operates 24 manufacturing facilities spread across 15 sites. Our strategic manufacturing sites have earned international accreditation from some of the world's most stringent global regulatory agencies. Our manufacturing capabilities encompass a wide range of product types, including steriles, oral solid doses, liquids, semi-solids, biologicals, and APIs.
Revenue (%)
32%
of Group revenue
7%
of Group gross profit
* Based on source of manufacture.
More on our business
